Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction

No abstract is available for this paper.

• Publication year

  2012

• Venue

  International Journal of Cancer

• Publication date

  2012-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.26191PMID 21607945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pillars article: T cell receptor antagonist peptides induce positive selection. Cell. 1994. 76: 17-27.

  2012cited by this paper
• Effect of NKG2D ligand expression on host immune responses

  2010cited by this paper
• Intact NKG2D-Independent Function of NK Cells Chronically Stimulated with the NKG2D Ligand Rae-1

  2010cited by this paper
• Obstructing Shedding of the Immunostimulatory MHC Class I Chain–Related Gene B Prevents Tumor Formation

  2009cited by this paper
• Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice.

  2009cited by this paper
• Oncogenic stress sensed by the immune system: role of natural killer cell receptors

  2009cited by this paper
• Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA1

  2008cited by this paper
• NKG2D ligands in tumor immunity

  2008cited by this paper
• Two Novel NKG2D Ligands of the Mouse H60 Family with Differential Expression Patterns and Binding Affinities to NKG2D1

  2008cited by this paper
• NK cells and cancer immunosurveillance

  2008cited by this paper
• NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.

  2008cited by this paper
• Soluble NKG2D ligands: prevalence, release, and functional impact.

  2008cited by this paper
• Promiscuity and the single receptor: NKG2D

  2007cited by this paper
• Immunobiology of human NKG2D and its ligands.

  2006cited by this paper
• Fas ligand–mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity

  2006cited by this paper
• Innate immune recognition and suppression of tumors.

  2006cited by this paper
• The DNA damage response arouses the immune system.

  2006cited by this paper
• Activation of V gamma 9V delta 2 T cells by NKG2D.

  2005cited by this paper
• NKG2D function protects the host from tumor initiation

  2005cited by this paper
• NKG2D is a costimulatory receptor for human naive CD8+ T cells.

  2005cited by this paper
• Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

  2005influential reference
• Costimulation through NKG2D Enhances Murine CD8+ CTL Function: Similarities and Differences between NKG2D and CD28 Costimulation1

  2005cited by this paper
• Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo1

  2005influential reference
• Activation of Vγ9Vδ2 T Cells by NKG2D1

  2005cited by this paper
• Cutting Edge: NKG2D Is a Costimulatory Receptor for Human Naive CD8+ T Cells

  2005cited by this paper
• Cutting Edge: Toll-Like Receptor Signaling in Macrophages Induces Ligands for the NKG2D Receptor 1

  2004cited by this paper
• Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets.

  2004cited by this paper
• A Switch in Costimulation from CD28 to 4-1BB during Primary versus Secondary CD8 T Cell Response to Influenza In Vivo1

  2004cited by this paper
• Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein

  2003cited by this paper
• Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells

  2003cited by this paper
• The role of the NKG2D immunoreceptor in immune cell activation and natural killing.

  2002cited by this paper
• Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

  2002cited by this paper
• Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding

  2002cited by this paper
• Redundancy of Direct Priming and Cross-Priming in Tumor-Specific CD8+ T Cell Responses1

  2001cited by this paper
• Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family

  2001cited by this paper
• Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells

  2001cited by this paper
• Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells.

  2001cited by this paper
• MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function

  2001cited by this paper
• MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function.

  2001cited by this paper
• Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

  2001cited by this paper
• Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

  2001cited by this paper
• Role of CD28 for the Generation and Expansion of Antigen-Specific CD8+ T Lymphocytes During Infection with Listeria monocytogenes1

  2001cited by this paper
• Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

  1999cited by this paper
• T cell receptor antagonist peptides induce positive selection.

  1994cited by this paper
• Exact prediction of a natural T cell epitope

  1991cited by this paper
• Introduction of soluble protein into the class I pathway of antigen processing and presentation.

  1988influential reference

• Targeting NKG2D/NKG2DL axis in cancer immunotherapy: mechanisms and therapeutic applications

  2026cites this paper
• Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.

  2024cites this paper
• Soluble NKG2D ligands impair CD8+ T cell antitumor function dependent of NKG2D downregulation in neuroblastoma

  2023cites this paper
• Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment

  2020cites this paper
• NKG2D signaling certifies effector CD8 T cells for memory formation

  2019cites this paper
• Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

  2019cites this paper
• M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

  2018cites this paper
• NKG2D: A Master Regulator of Immune Cell Responsiveness

  2018cites this paper
• Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy

  2018cites this paper
• More than Decoration: Roles for Natural Killer Group 2 Member D Ligand Expression by Immune Cells

  2018cites this paper
• DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

  2018cites this paper
• Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors

  2017cites this paper
• NKG2D: A versatile player in the immune system.

  2017cites this paper
• Identification de nouveaux biomarqueurs permettant la caractérisation des lymphocytes T CD8 mémoires innés

  2016cites this paper
• NKG2D signaling in cancer immunosurveillance

  2015cites this paper
• Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

  2015cites this paper
• Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC

  2015cites this paper
• Recognition of tumors by the innate immune system and natural killer cells.

  2014cites this paper
• New prospects on the NKG2D/NKG2DL system for oncology

  2013cites this paper
• Trial Watch

  2013cites this paper
• Modulation des fonctions des lymphocytes T CD8 par l'Interleukine-4 et les cytokines de la famille γc

  2011cites this paper